Clinical Trial Results:
Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C infektion who relapsed after Interferon alfa / Ribavirin combination treatment
Summary
|
|
EudraCT number |
2005-001207-19 |
Trial protocol |
DE |
Global completion date |
16 Dec 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Feb 2020
|
First version publication date |
02 Feb 2020
|
Other versions |
|
Summary report(s) |
2005-001207-19 Trela result summary 12_2009 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.